Cover Image

EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID)

The article describes the monitoring of severe cryopyrin-associated syndrome (syndrome CINCA/NOMID). The following clinical case indicates successful application of homogeneous antibodies to interleukin 1 - canakinumab - in patient with chronic neurologic dermatic articular syndrome. Fever, rush and...

Full description

Saved in:

Bibliographic Details
Main Authors:	T. V. Sleptsova (Author), E. I. Alexeeva (Author), K. V. Savost'yanov (Author), A. A. Pushkov (Author), A. G. Nikitin (Author), T. M. Bzarova (Author), S. I. Valieva (Author), A. N. Fetisova (Author), A. V. Pakhomov (Author), N. V. Zhurkova (Author), R. V. Denisova (Author), K. B. Isaeva (Author), E. G. Chistyakova (Author)
Format:	Book
Published:	"Paediatrician" Publishers LLC, 2014-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Experience of the successful treatment with canakinumab of a patient with NLPC4-associated autoinflammatory syndrome with enterocolitis
by: T. V. Sleptsova, et al.
Published: (2016)

Cryopyrin-associated periodic syndromes (CAPS): report on two cases (Muckle-Wells syndrome (MWS) and CINCA/NOMID)
by: Kuzmina NN, et al.
Published: (2011)

Effect of anakinra on arthropathy in CINCA/NOMID syndrome
by: Kaneko Utako, et al.
Published: (2010)

Treating TRAPS Syndrome with a Previously Undescribed TNF α Gene Receptor Mutation Successfully with Canakinumab
by: T. V. Sleptsova, et al.
Published: (2016)

High Efficiency of Kanakinumabum for a Patient with a Late Diagnosed Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA)
by: T. V. Sleptsova, et al.
Published: (2015)

EXPERIENCE OF THE SUCCESSFUL CANAKINUMAB TREATMENT OF A PATIENT WITH UNDIFFERENTIATED AUTOINFLAMMATORY SYNDROME
by: Tatyana V. Sleptsova, et al.
Published: (2016)

Our experience with the use of the Interleukin-1 receptor antagonist in the treatment of the patient with CINCA/NOMID syndrome (case study - 5 years of therapy)
by: Vargova V, et al.
Published: (2011)

Diagnosis of NLRP3 somatic mosaicism in CINCA/NOMID patients using next-generation sequencing
by: Nakahata T, et al.
Published: (2011)

Cryopyrin-Associated Periodic Syndrome (CAPS) Caused by c.943A>G Variant of NLRP3 Gene: Clinical Case
by: Ivan A. Kriulin, et al.
Published: (2019)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
by: Martini A, et al.
Published: (2011)

CASE OF NON-SEVERE CONGENITAL NEPHROTIC SYNDROME
by: I. S. Kostushina, et al.
Published: (2014)

Clinical and Molecular Genetic Features of Autoinflammatory Syndromes in Children
by: Е. I. Alexeeva, et al.
Published: (2015)

Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China
by: Xiaona Zhu, et al.
Published: (2024)

CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS
by: E. I. Alexeeva, et al.
Published: (2014)

DIAGNOSIS AND TREATMENT OF PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME
by: A. L. Kozlova, et al.
Published: (2015)

Cryopyrin-associated periodic syndrome Muckle - Wells: A Case Report
by: N. V. Shakhova, et al.
Published: (2023)

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome
by: Abdulkadir A. Elmi, et al.
Published: (2019)

EXPERIENCE OF INTRAVENOUS INJECTION OF NORMAL HUMAN IMMUNOGLOBULIN IN A PATIENT WITH KAWASAKI SYNDROME
by: T. V. Sleptsova, et al.
Published: (2014)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
by: Takada H, et al.
Published: (2011)

CRYOPYRIN ASSOCIATED PERIODIC SYNDROME
by: M. Gattorno
Published: (2013)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to <it>V198M</it> mutation responds to canakinumab - a case report
by: Kuemmerle-Deschner Jasmin B, et al.
Published: (2011)

National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
by: Gallizzi R, et al.
Published: (2011)

CLINICAL CASE OF CANAKINUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2013)

Could canakinumab be used for COVID-19?
by: V. A. Otdelenov, et al.
Published: (2020)

MANAGEMENT OF A PATIENT WITH SEVERE COURSE OF PSORIATIC ARTHRITIS
by: E. I. Alexeeva, et al.
Published: (2013)

EFFICACY OF ETANERCEPT TREATMENT AS A SECOND TNF α INHIBITOR IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS AND PRIMARY AND SECONDARY INEFFICIENCY OR INTOLERANCE OF INFLIXIMAB
by: E. I. Alexeeva, et al.
Published: (2012)

Brief Guidelines on Preparation of Manuscripts Containing Information on the Results of Molecular Genetic Research
by: Alexander A. Pushkov, et al.
Published: (2018)

Treatment of refractory Yao syndrome with canakinumab
by: Caroline J. Brailsford, MS, et al.
Published: (2022)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
by: Kümmerle-Deschner J, et al.
Published: (2008)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
by: Justin Gillespie, et al.
Published: (2010)

RETROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF HYPODERMIC METHOTREXATE INJECTIONS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
by: E. I. Alexeeva, et al.
Published: (2013)

EXPERIENCE OF RITUXIMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: E. I. Alekseeva, et al.
Published: (2012)

Evaluation of Efficacy and Safety of Etanercept Therapy in Patients with Early and Late Juvenile Idiopathic Arthritis without Systemic Manifestations
by: T. M. Bzarova, et al.
Published: (2015)

Molecular and Genetic Basis of Hereditary Connective-Tissue Diseases Accompanied by Frequent Fractures
by: G. T. Yakhyaeva, et al.
Published: (2016)

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis
by: Mikhail M. Kostik, et al.
Published: (2022)

ADALIMUMAB IN TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2013)

LONG TERM FOLLOW-UP ON EFFECTIVENESS AND SAFETY OF ETANERCEPT IN JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS
by: A. A. Baranov, et al.
Published: (2015)

ASSESSMENT OF THE QUALITY OF LIFE OF PATIENTS WITH THE JUVENILE IDIOPATHIC ARTHRITIS TREATED BY THE ETANERCEPT
by: A. N. Fetisova, et al.
Published: (2014)

CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
by: Ye. I. Alekseeva, et al.
Published: (2014)

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
by: Angel Luis Salcedo-Mingoarranz, et al.
Published: (2023)